Among patients with different PD-L1 expression status and histological features, patients in the PD-L1 tumor cell proportion score ≥50% and non-squamous NSCLC subgroup showed better mPFS and mOS in the clinical trial which may translate into longer QALYs, and resulting in higher ICERs under nearly the same cost of medication. The gene discussed is CD274; the disease is neoplasm.